Reuters logo
REFILE-BRIEF-FDA Says Approves Mylan GmbH's Ogivri As First Biosimilar For Treatment Of Certain Breast, Stomach Cancers
December 1, 2017 / 3:42 PM / 13 days ago

REFILE-BRIEF-FDA Says Approves Mylan GmbH's Ogivri As First Biosimilar For Treatment Of Certain Breast, Stomach Cancers

(Corrects to add ‘Like Herceptin’ in the second bullet)

Dec 1 (Reuters) - FDA:

* FDA SAYS APPROVES MYLAN GMBH‘S OGIVRI AS A FIRST BIOSIMILAR FOR TREATMENT OF CERTAIN BREAST AND STOMACH CANCERS

* FDA - LIKE HERCEPTIN, OGIVRI LABEL CONTAINS BOXED WARNING TO ALERT HEALTH CARE PROFESSIONALS, PATIENTS ABOUT INCREASED RISKS OF HEART DISEASE,INFUSIONS REACTIONS,OTHERS Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below